- Stand Up To Cancer (SU2C) is a groundbreaking movement to accelerate innovative cancer research that gets new therapies to patients quickly and saves lives now. Put simply, SU2C mandates collaboration among the best and the brightest to achieve patient benefits.
People also ask
What does SU2C stand for?
What is the SU2C telethon?
What is SU2C and when was it first broadcast?
What is stand up to cancer?
Stand Up to Cancer is a charitable program of the Entertainment Industry Foundation. SU2C aims to raise significant funds for translational cancer research through online and televised efforts. Central to the program is a telethon that was first televised by four major broadcast networks in over 170 countries on September 5, 2008. SU2C raised over $100 million after that evening's broadcast. Funds collected by Stand Up to Cancer are then distributed by the American Association for Cancer Researc
SU2C UK say their aim is to "accelerate progress in life-saving cancer research," and says that "Stand Up To Cancer takes developments in the labs and accelerates them into brand new tests and...
Stand Up To Cancer (SU2C) was created by a group of nine women in the entertainment and news community whose lives have all been affected by cancer in profound ways.
SU2C Catalyst is a new approach to rapidly explore novel uses of medicines, devices and/or diagnostics to accelerate research on cancer prevention, detection and treatment. Concept. SU2C Catalyst establishes a mechanism through which industry and academic scientists in the cancer community conduct SU2C collaborative research projects that will deliver significant benefits for patients and society, accelerating the development of new treatments and, where appropriate, combination therapies.
Apr 15, 2018 · CHICAGO – April 15, 2018 – Stand Up To Cancer announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease. The SU2C Multiple Myeloma Dream Team will be led by Irene Ghobrial, MD, associate professor of medicine at Dana-Farber Cancer Institute (DFCI) in Boston and co-director of the Center for ...